Navigation Links
Pregnancy may slow -- not accelerate -- progression to AIDS
Date:9/19/2007

A new study may help put to rest fears that pregnancy accelerates progression to full-blown AIDS in women with HIV receiving antiretroviral therapy. The study, published in the October 1st issue of the Journal of Infectious Diseases and now available online, revealed that pregnancy may, in fact, slow disease progression in these women.

Before the advent of highly active antiretroviral therapy (HAART), many women with HIV infection or AIDS were told that becoming pregnant would be unwise because there was thought to be a 25 percent risk of transmitting the virus to the child and that the effects of pregnancy on disease progression were unclear. It is now clear that the use of HAART in pregnancy can reduce the HIV transmission to the newborn to approximately 1 percent, but the effects of pregnancy on the HIV-infected woman remain unknown.

To determine the effects of pregnancy on HIV disease progression in the HAART era, Timothy R. Sterling, MD, and colleagues at Vanderbilt University performed an observational study of HIV-infected women between 1997 and 2004. Disease progression was defined as experiencing an AIDS-defining event such as Kaposis sarcoma, Pneumocystis carinii pneumonia, or Candida fungal infection of the esophagus; or death. Of the 759 women studied, 71 percent (540) were receiving HAART. Eighteen percent (139) of women studied had one or more pregnancy during this study.

Based on the results of studies conducted before HAART, researchers had expected there might be no difference in HIV disease progression between pregnant and non-pregnant women. What Sterling and colleagues found was that women who became pregnant actually had a lower risk of HIV disease progression and were healthier than women who did not become pregnant. Women experienced a lower risk of disease progression both before and after pregnancy. This may be a result of the healthier immune status of women who become pregnant and/or a beneficial interaction between pregnancy and HAART.

Although the pregnant women in the study were younger than the non-pregnant women, had higher initial CD4+ lymphocyte counts (white blood cells that are attacked by HIV), and a smaller amount of HIV RNA in their plasma, their risk of disease progression remained lower even after factoring in these differences. Nor did it matter that the pregnant women also were more likely to receive HAART and more likely to attend clinic appointments.

Additionally, women with multiple pregnancies during follow-up tended to have a lower risk of disease progression than did women with only one pregnancy. Sterling notes, This apparent dose-response relationship supports a possible protective effect of pregnancy on disease progression. Pregnancy is associated with a complex set of immunological changes during the gestation period, which may provide additional benefit to the mothers health.

In an accompanying editorial, Kathryn Anastos, MD, of the Albert Einstein College of Medicine emphasized that although understanding of this complexity is not complete,

Dr. Sterlings study gives hope that correlative studies of the immune response to pregnancy and the influence of pregnancy on HIV disease may help to provide the needed information.

Dr. Anastos suggested that this information may be of particular significance to women in resource-limited communities, who generally bear more children than do those in higher-resource communities. She noted that women can now have greater confidence that in addition to protecting their children from [mother-to-child transmission of HIV] with HAART, their own health will not be compromised by pregnancy, which would place their children at long-term riskthe findings by Sterling and coworkers suggest that at least for HIV disease progression, the odds may be in their favor.

Fast facts:

1) Women who became pregnant had a lower risk of HIV disease progression and were healthier than women who did not become pregnant.

2) Women with multiple pregnancies during follow-up tended to have a lower risk of disease progression than women with one pregnancy.

3) Currently, nearly all mother-to-child transmission can be prevented by the administration of appropriate HAART regimens during pregnancy and delivery, with postnatal treatment for the infant.


'/>"/>

Contact: Steve Baragona
sbaragona@idsociety.org
703-299-0412
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. Serum Progesterone Helps Stratify Ectopic Pregnancy Risk
2. IMA wants members not to do sex determination tests during pregnancy
3. Pregnancy Blues
4. Grandmother’s diet in pregnancy can affect grandchildren’s blood sugr
5. Gel prevents pregnancy
6. Cigerettes unsafe during pregnancy
7. Smoking Delays Pregnancy
8. Pregnancy should not be confined
9. Link between chlorine byproducts and pregnancy risks
10. Asprin aids in pregnancy
11. Toxins linked with pregnancy loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... Dr. Jig Patel is ... Schaumburg, IL, with or without a referral. Understanding the difficulties that face people who ... when they choose this permanent alternative to removable dentures and bridges. Not only does ...
(Date:7/20/2017)... , ... July 19, 2017 , ... ... $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral dental ... health care needs in rural and underserved areas. , The Predoctoral Pediatric Training ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... may sometimes lead to, or worsen, varicose veins in some patients, according to ... while avoiding certain not-so-good practices, like excessive sitting or standing, or regularly nicking ...
(Date:7/18/2017)... Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking place ... will be speaking on the therapeutic benefits of medical cannabis for both pediatric and ...
(Date:7/18/2017)... Calif. (PRWEB) , ... July 18, 2017 , ... The results of an international clinical ... a drug therapy for a severe type of muscular dystrophy holds promise for a subgroup ... , Craig McDonald and colleagues at 53 study sites in 18 countries describe ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... -- The Institute for In Vitro Sciences (IIVS), a ... a VITROCELL® inhalation exposure system thanks to a generous ... which is designed to replace animals in inhalation testing, ... airborne test materials in an environment that mimics the ... testing combustible tobacco products, as well as next generation ...
(Date:7/6/2017)... July 6, 2017 ThriveRx, the nutrition division of Diplomat Specialty ... to thrive on nutrition support. To celebrate its anniversary, ThriveRx ... has a fresh new look with improved organization to create the best ... ... "We,ve made ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology: